#### **CHIMERIX INC**

Form 4

September 16, 2014

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB

**OMB APPROVAL** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

obligations may continue. See Instruction

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Sanderling Venture Partners V, LP

400 SOUTH EL CAMINO REAL,

(Street)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(Last)

(First)

(Middle)

CHIMERIX INC [CMRX]

below)

(Check all applicable)

Officer (give title

3. Date of Earliest Transaction (Month/Day/Year)

Director

\_X\_\_ 10% Owner \_\_ Other (specify

09/12/2014

**SUITE 1200** 

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

SAN MATEO, CA 94402

(City)	(State) (	(Zip) Tabl	e I - Non-D	erivative Se	curiti	es Acqı	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securitie on(A) or Disp (Instr. 3, 4	oosed of and 5)  (A) or	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(Insure and I)		See
Common Stock	09/12/2014		<u>J(1)</u>	164,600	D	\$ 0	3,766,100	I	Footnote (2)
Common Stock	09/12/2014		J <u>(3)</u>	40,300	D	\$0	3,725,800	I	See Footnote (2)
Common Stock	09/12/2014		J <u>(4)</u>	81,200	D	\$0	3,644,600	I	See Footnote
Common Stock	09/12/2014		J <u>(5)</u>	133,900	D	\$0	3,510,700	I	See Footnote

Edgar Filing: CHIMERIX INC - Form 4

Common Stock  $J_{\underline{(6)}}$  199,300 D \$ 0 3,311,400 I Footnote  $\frac{(2)}{(2)}$ 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	<b>:</b>	ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Dolotionchine

# **Reporting Owners**

Reporting Owner Name / Address	Keiauonsinps					
	Director	10% Owner	Officer	Other		
Sanderling Venture Partners V, LP						
400 SOUTH EL CAMINO REAL, SUITE 1200		X				
SAN MATEO, CA 94402						

## **Signatures**

See Signatures Included in Exhibit 99.2 09/16/2014

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pro rata distribution for no consideration by Sanderling Venture Partners V, L.P. to its partners.

Reporting Owners 2

### Edgar Filing: CHIMERIX INC - Form 4

- (2) See attached Exhibit 99.1
- (3) Pro rata distribution for no consideration by Sanderling V Biomedical, L.P. to its partners
- (4) Pro rata distribution for no consideration by Sanderling V Biomedical Co-Investment Fund, L.P. to its partners.
- (5) Pro rata distribution for no consideration by Sanderling Venture Partners V Co-Investment Fund, L.P. to its partners.
- (6) Pro rata distribution for no consideration by Sanderling Venture Partners VI Co-Investment Fund, L.P. to its partners.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.